Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients

Substance Use Disorder (SUD) Clinical Trial

Official title:

Predicting Early Treatment Termination (Dropout) and Post-treatment Clinical Outcome From Neuropsychological Functions in Abstinent Substance Use Dependent (SUD) Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03220373
• Other study ID #: 2015/11288
• Status: Active, not recruiting
• Start date: March 7, 2017
• Est. completion date: December 31, 2029

Study information

• Verified date: January 2024
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder.

Description:

This project collects the neuropsychological profile of residential SUD patients, in addition to treatment length, exit reason, hospital journal data and post-treatment clinical outcome data. The project aims to identify clinically relevant neurocognitive domains that predict treatment dropout and post-treatment clinical outcome. This will make it possible for future clinicians to focus their effort on neurocognitive functions most relevant for this particular patient group.

RESEARCH QUESTIONS:

1. What neurocognitive domain (and sub-domain) are the strongest predictor of treatment drop-out and retention?

2. What neurocognitive domain (and sub-domain) are the strongest predictor of post-treatment clinical outcome variables such as drug use, health and social integration.

3. Will data on treatment length, age, gender, substance abuse history or psychiatric co-morbidity predict outcome independently, or in interaction with, the neuropsychological profile?

This longitudinal prospective cohort study aims for a continuous collection of neuropsychological data baseline and post-treatment follow-up data until 2030.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2029
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Substance Use Disorder (SUD) patients.

• 18 years or older.

• Qualified to consent to research participation.

• Able to speak and write in Norwegian.

Exclusion Criteria:

• Not qualified to consent to research participation.

• Insufficient understanding of Norwegian.

Related Conditions & MeSH terms

• Substance Use Disorder (SUD)
• Substance-Related Disorders

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Exit reason	Reason for terminating residential SUD treatment (Treatment completed or Drop-out)	On average 3 months
Primary	Treatment retention	Number of days in treatment	On average 3 months
Secondary	Substance use	DUDIT (Drug Use Disorders Identification Test)	1 year after neuropsychological assessment
Secondary	Psychological distress	SCL-10 (Symptom Checklist)	1 year after neuropsychological assessment
Secondary	Quality of Life	QoL-5 (Quality of Life)	1 year after neuropsychological assessment
Secondary	ADHD symptoms	ASRS (ADHD Self-Report Scale)	1 year after neuropsychological assessment
Secondary	Income	Nature of income	1 year after neuropsychological assessment
Secondary	Housing	Nature of present accommodation	1 year after neuropsychological assessment